Eligible adolescents and emerging adults (ages 12-25) who have used cannabis in the past year will attend 1-2 laboratory visits. They will complete a series of interviews and self-report measures, including assessment of cannabis quantity and frequency, subjective effects of cannabis, and problems due to cannabis use. They will provide a urine sample for analysis of a THC metabolite and they will provide a blood sample for analysis of genes related to cytochrome P450 enzyme activity, which are thought to be associated with metabolism of THC.
The study will test a computerized treatment with subjects ages 13-17 years who are seeking treatment for alcohol and/or cannabis use. Youth will be recruited from the Center for Drug and Alcohol Programs (CDAP) Clinic in the Department of Psychiatry at MUSC. Follow-up assessments will be conducted at one- and three-months following treatment.
Human subjects are being recruited for the proposed study to participate in usability testing for a virtual reality technology tool to be refined for assessment and prevention of risky sexual and substance use behaviors. Specifically, 15 adolescents, 15 young men, and 15 front line health care providers will participate in qualitative interviews and focus groups. Targeted enrollment is based on estimates from the existing clinical population treated by the local clinics from which participants will be recruited and the candidate's experience conducting clinical studies at these sites.
This study will examine the effects of early childhood adversity on stress and craving among individuals with opioid use disorder. Study participants will complete a total of three visits, including a 1-month follow-up visit. Participants will be asked to complete questionnaires about thier mood, anxiety, drug use, craving and adverse childhood events. They will listen to personalized scripts about a stressful situation, a time when they used opioid and a relaxing situation and their heart rate, skin conductance and cortisol are measured.
The purpose of this study is to determine if certain chemicals in the body, called endocannabinoids, are affected by heavy marijuana use or marijuana withdrawal. Participation lasts approximately five weeks. In the first week, participants can use marijuana as usual and will complete mobile assessments asking about their current feelings four times each day for seven days. Participants will also complete three 5-hour laboratory visits during this week to assess levels of endocannabinoids in the blood at different times of day. One month after the first laboratory visit, participants will complete the same tasks (three laboratory visits and daily mobile assessments) while maintaining abstinence from marijuana for one week.
This Phase II clinical research study evaluates both the safety and effectiveness of an FDA-regulated medication presently in the initial stages of development for alcohol use disorder treatment (GET73), and will test whether GET73 alters brain chemicals and function, response to alcohol ingestion, and the desire for alcohol. Participants will be randomly assigned to one of two medication treatment groups (GET73 or placebo). Study medication will be taken for 8 days, with approximately 4 study visits, and a "bar-lab" procedure and 2 MRI brain imaging scans will be completed. Questionnaires and clinical interview measures will be completed at study visits along with consistent assessment of potential side effects from study medication.
This study proposes to collect pilot data that will inform a future grant application. We propose to complete interviews (60 min) on 25 individuals who are currently or have previously used opioids and are either currently on MAT or chose to not begin MAT. Semi-structured interviews will identify (1) what individual and treatment factors helped participants initiate MAT or, conversely, inhibited engagement in MAT, (2) what concerns they had about starting MAT, and (3) encouraging them to reflect on what additional information could have helped them initiate MAT sooner. Eligible participants will be compensated $20 for their participation in the study.
The purpose of this study is to develop transcranial magnetic stimulation (TMS), specifically TMS at a frequency known as theta burst stimulation (TBS), to see how it affects the brain and changes the brain's response to alcohol-related pictures. TMS and TBS are stimulation techniques that use magnetic pulses to temporarily excite specific brain areas in awake people (without the need for surgery, anesthetic, or other invasive procedures). TBS, which is a form of TMS, will be applied over the medial prefrontal cortex, (MPFC), which has been shown to be involved with drinking patterns and alcohol consumption. This study will test whether TBS can be used as an alternative tool to reduce the desire to use alcohol and reducing the brain's response to alcohol-related pictures.
This study is looking at an investigational medication called EMB-001, which is a combination of metyrapone and oxazepam, to see if it may be an effective treatment for cocaine use disorder. Participants will undergo screening procedures to determine eligibility, and eligible participants will take either EMB-001 or placebo twice a day for 13 weeks. During this time, participants will come to the office two times a week to meet with study personnel, and they will attend a one-month follow-up visit.
The purpose of this research study is to understand if high brain iron in individuals who use cocaine is related to the severity of cocaine use disorder. We will use non-invasive brain MRI to examine if high brain iron is associated with 1) abnormal brain circuits, and 2) behavioral and cognitive problems. The consists of a screening visit to determine eligibility and an MRI scanning visit.